Literature DB >> 14615247

HIV infection reduces skin graft survival in burn injuries: a prospective study.

S Mzezewa1, K Jönsson, E Sibanda, M Aberg, L Salemark.   

Abstract

UNLABELLED: Impaired survival of skin grafts has been noted in human immunodeficiency virus (HIV) infected patients, but the reason is not known. Alterations in inflammatory response, which might be recorded as an imbalance in cytokine production, have been implicated. The aim of this study was to determine the impact of HIV infection in patients with burn injuries by comparison of split skin graft survival, T lymphocyte count and cytokine levels in HIV-infected and non HIV-infected patients in relation to healthy and HIV-infected nonburnt volunteers.Fifty-four patients with deep dermal burns were included. Fifteen patients' were HIV-infected. Thirteen healthy and 15 HIV-infected, volunteers were recruited as controls. The burnt surface area was traced on a transparent plastic sheet and converted to area. Graft survival on day of discharge/regraft for non HIV-infected patients was 69%, and in HIV-infected 22%, (p<0.05). The median length of hospital stay for early excision among non HIV-infected patients was 21 (12-53) days and for HIV-infected, 41 days (p<0.05). Serum protein levels in HIV-infected patients were elevated compared to non HIV-infected patients (p<0.05). CD4+ lymphocytes were depressed in HIV-infected volunteers and HIV-infected burn patients compared to healthy volunteers (p<0.05). CD8+ lymphocytes were elevated in HIV-infected volunteers compared to non HIV-infected burn patients. Pro-inflammatory cytokine levels of Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interferon-gama (IFN-gamma) and tumour necrosis factor alpha (TNF-alpha) were depressed in HIV-infected volunteers compared to healthy volunteers and non HIV-infected burn patients. The pro-inflammatory cytokine IFN-gamma did not increase after burn injury in HIV-infected burns patients as did IL-2, IL-6 and TNF-alpha (p<0.05). Anti-inflammatory cytokine levels of IL-4 were elevated in HIV-infected volunteers compared to healthy volunteers and burn patients (p<0.05).
CONCLUSION: Graft survival after split skin grafting of burn wounds in HIV-infected patients is impaired and hospital stay is prolonged. HIV infection result in immune dysregulation, which might be related to impaired skin graft survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615247     DOI: 10.1016/j.bjps.2003.08.010

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  6 in total

1.  Relevance of electronic health information to doctors in the developing world: results of the Ptolemy Project's Internet-based Health Information Study (IBHIS).

Authors:  Kirsteen R Burton; Andrew Howard; Massey Beveridge
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

Review 2.  Burn wound infections.

Authors:  Deirdre Church; Sameer Elsayed; Owen Reid; Brent Winston; Robert Lindsay
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  Abdominal surgical site infections: a prospective study of determinant factors in Harare, Zimbabwe.

Authors:  David Muchuweti; Kent U G Jönsson
Journal:  Int Wound J       Date:  2013-09-19       Impact factor: 3.315

4.  Prevalence of HIV infection among burn patients: is there a relationship with patients' outcomes?

Authors:  Seyed Hamid Salehi; Kamran As'adi; Seyedeh Azam Tabatabaeenezhad; Mohammad Naderan; Saeed Shoar
Journal:  Int Wound J       Date:  2015-12-15       Impact factor: 3.315

5.  HIV seroprevalence and its effect on outcome of moderate to severe burn injuries: A Ugandan experience.

Authors:  Robert Ssentongo; Ignatius Kakande; Phillipo L Chalya
Journal:  J Trauma Manag Outcomes       Date:  2011-06-09

Review 6.  Viral Infections in Burn Patients: A State-Of-The-Art Review.

Authors:  Jacek Baj; Izabela Korona-Głowniak; Grzegorz Buszewicz; Alicja Forma; Monika Sitarz; Grzegorz Teresiński
Journal:  Viruses       Date:  2020-11-17       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.